YAKHAK HOEJI

Table. 2. Table 2

Change in medical and pharmaceutical expenses for lung cancer per patient by year†

Classification	2015	2016	2017	2018	2019	2020	CAGR
Medical expenditure per patient
Total	782	838	864	1,046	1,160	1,145	7.9%
Drug prescription group	766	831	847	1,039	1,157	1,181	9.0%
Anti-cancer drug prescription group	1,479	1,793	1,924	2,272	2,358	2,939	14.7%
Immunotherapy	-	-	1,616	2,593	2,455	3,173	25.2%
Targeted therapy	1,320	1,384	1,503	2,034	1,703	2,741	15.7%
Other chemotherapy	1,381	1,733	1,738	1,777	1,917	1,918	6.8%
Immuno/Targeted therapy	1,344	1,443	1,621	2,374	2,137	3,125	18.4%
Pharmaceutical expenditure per patient^‡
Drug prescription group	300	312	299	416	460	536	12.3%
Anti-cancer drug prescription group	447	595	646	957	1,003	1,396	25.6%
Immunotherapy	-	-	1,056	1,942	1,762	2,405	31.6%
Targeted therapy	1,003	1,153	1,119	1,590	1,436	1,984	14.6%
Other chemotherapy	141	252	258	225	233	228	10.1%
Immuno/Targeted therapy	1,021	1,202	1,188	1,835	1,708	2,301	17.6%

^*unit: 10 thousand won, %

^†Marked with ‘-‘ before the introduction of reimbursements

^‡Calculation the proportion of pharmaceutical costs per patient to medical costs per patient by drug class

Abbreviation: CAGR, Compound Annual Growth Rate